Znn3bq.jpeg
±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 610  |  »Ø¸´: 0

Äϱ±ÔÆ

½ð³æ (СÓÐÃûÆø)

[½»Á÷] Ïã¸Û¿Æ¼¼´óѧ¸ßµÈÑо¿ÔºÕÐÆ¸Ë«ÌØÒìÐÔ¿¹ÌåÑз¢²©Ê¿ºó

Ïã¸Û¿Æ¼¼´óѧ¸ßµÈÑо¿ÔºJockey Club Institute for Advanced Study/ Division of Life ScienceÕÐÆ¸Ë«ÌØÒìÐÔ¿¹ÌåÑз¢²©Ê¿ºó

ÉêÇëÈËÐèÒª¾ßÓÐ
£¨1£©ÉúÎﻯѧ/ÉúÎï¿ÆÑ§»òÏà¹ØÑ§¿ÆµÄ²©Ê¿Ñ§Î»£»
£¨2£©ÔÚÒÔÏÂÁìÓòÖ®Ò»ÖоßÓзḻµÄ¾­Ñé»ò±³¾°£ºÏ¸°ûÉúÎïѧ£¬Ï¸°ûÐźŴ«µ¼ºÍ/»òµ°°×ÖÊ¿ÆÑ§£»
£¨3£©ÔÚ²¸È鶯Îïϸ°ûÅàÑø£¬¿ª·¢ºÍÖ´ÐлùÓÚϸ°ûµÄ¹¦Äܲⶨ£¬¸ßͨÁ¿É¸Ñ¡£¨ÀýÈçELISA£©ºÍ/»òµ°°×ÖÊ´¿»¯ºÍ·ÖÎö·½ÃæµÄ·á¸»¾­Ñ顣ʹÓÃFlowJoÔÚÁ÷ʽϸ°ûÒǺÍÊý¾Ý·ÖÎö·½ÃæµÄ¾­Ñ齫ÊÇÒ»¸öÓÅÊÆ¡£
£¨4£©ºòÑ¡È˱ØÐëÓµÓÐÏã¸Û±¾µØ´óѧ»òÊÀ½çÅÅÃûǰ100´óѧµÄ²©Ê¿Ñ§Î»¡£Çë×¢Ò⣬Õâµã·Ç³£ÖØÒª£¬ÊDZØÐëµÄ¡£ÒòΪºòÑ¡È˵Äн½ðÊÇÏã¸ÛÕþ¸®Ö¸¶¨µÄ¼Æ»®ÖгöµÄ¡£ÕâµãÊÇ»ù±¾ÒªÇóÖ®Ò»¡£ÈϿɵÄÊÀ½ç´óѧÅÅÃû°üÀ¨Quacquarelli Symonds World University Rankings£¬ÉϺ£½»Í¨´óѧÊÀ½ç´óѧѧÊõÅÅÃû»òTimes Higher Education World University Rankings¡£»ñµÃµÄѧλӦÔÚ¿ÆÑ§£¬¼¼Êõ£¬¹¤³ÌºÍÊýѧ£¨stem£©Ïà¹ØÑ§¿ÆÖС£

Æðн½«Óë×ÊÀúºÍ¾­ÑéÏà³Æ¡£ ¸½¼Ó¸£Àû°üÀ¨Äê¼Ù£¬Ò½ÁƺÍÑÀ¿Æ¸£Àû¡£
ÈçÈôÉêÇ룬Çë²ÎÔÄÒ»ÏÂÁ´½Ó¡£
https://hrmsxprod.psft.ust.hk:8044/psp/hrmsxprod/EMPLOYEE/HRMS/c/HRS_HRAM.HRS_CE.GBL?Page=HRS_CE_JOB_DTL&Action=A&JobOpeningId=5435&SiteId=1000&PostingSeq=1

=================
English Version
Job Posting Details
Positions for Post-doctoral Fellows are available in the IAS HKUST - Scripps R&D Laboratory to conduct research projects in biomedical sciences.
The IAS HKUST ¨C Scripts R&D Laboratory is co-supervised by Prof. Paul Schimmel (The Scripps Research Institute; HKUST IAS Visiting Professor) and Prof. Mingjie Zhang (Kerry Holdings Professor of Science and Chair Professor of Life Science, HKUST).  It aims to elucidate the molecular mechanisms by which extracellular signaling molecules that originate from the aminoacyl-tRNA synthetase (AARS) family use to modulate diverse biology, as well as to translate the discovery of novel biological pathways to develop innovative therapeutics with improved outcomes for patients.  The appointees will work closely with aTyr Pharma (a US biotech with clinical-stage molecules based on the AARS-family) on projects leading to the development of new therapeutics, and have opportunities for publication in high-impact journals as well as for filing of US patents.  A project has recently been initiated, partially funded by the Hong Kong Innovation and Technology Commission (ITC), for creation of an innovative bispecific antibody drug-discovery platform and implementation of this cutting-edge platform to rapidly generate therapeutic candidates selectively targeting extracellular receptors of AARS.
More laboratory information is available in the website:
https://ias.ust.hk/web/ias/eng/p ... tid=4&sid=6
Applicants should have (i) a PhD degree in biochemistry/biological sciences or a related discipline; (ii) strong experience or background in one of the following areas: cell biology, cell signaling, and/or protein science; and (iii) extensive experience in culture of mammalian cells, developing and performing cell-based functional assays, high-throughput screening (e.g. ELISA), and/or protein purification and analysis.  Experience in flow cytometry and data analysis using FlowJo would be an advantage.  (iv) The candidate must possess a doctoral degree from either a Hong Kong university or an institution are among the top 100 institutions for related subjects in the latest publication of world university ranking tables, including the Quacquarelli Symonds World University Rankings, Shanghai Jiao Tong University (Academic Ranking of World Universities) or Times Higher Education World University Rankings. The degree obtained should be in a science, technology, engineering and mathematics (STEM) related discipline.
The successful candidates should be self-motivated, capable of working independently with minimal supervision, and attentive to details.  They should also have excellent analytical and problem-solving skills as well as verbal and written communication skills.  Immediate availability is highly preferred. (Duration: 1 year, renewable)
Starting salary will be commensurate with qualifications and experience.  Fringe benefits including annual leave, medical and dental benefits will be provided where applicable.

To apply, please refer to the following link for details.
https://hrmsxprod.psft.ust.hk:8044/psp/hrmsxprod/EMPLOYEE/HRMS/c/HRS_HRAM.HRS_CE.GBL?Page=HRS_CE_JOB_DTL&Action=A&JobOpeningId=5435&SiteId=1000&PostingSeq=1
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ Äϱ±ÔÆ µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 0854µç×ÓÐÅÏ¢319Çóµ÷¼Á£¨½ÓÊÜ¿çרҵµ÷¼Á£© +4 ÐÇÐDz»Õ£ÑÛà¶ 2026-04-05 4/200 2026-04-07 16:19 by zb521a
[¿¼ÑÐ] 081200-11408-276ѧ˶Çóµ÷¼Á +4 ´Þwj 2026-04-02 4/200 2026-04-07 16:06 by åÐÒ£cocoa
[¿¼ÑÐ] 318Çóµ÷¼Á +3 ÀîÇàɽɽɽ 2026-04-07 3/150 2026-04-07 15:09 by shdgaomin
[¿¼ÑÐ] Ò»Ö¾Ô¸211£¬»¯Ñ§Ñ§Ë¶£¬310·Ö£¬±¾¿ÆÖصãË«·Ç£¬Çóµ÷¼Á +4 ŬÁ¦·Ü¶·112 2026-04-07 4/200 2026-04-07 10:30 by unicornone
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á 348·Ö +8 °¦ÎÒ³¬ÕæÃ»ÕÐÁË 2026-04-06 8/400 2026-04-07 08:19 by houyaoxu
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +10 Ò»ÑùYWY 2026-04-06 10/500 2026-04-06 21:05 by lbsjt
[¿¼ÑÐ] 071000ÉúÎïѧµ÷¼Á +7 À­ÌáÌÒ 2026-04-06 7/350 2026-04-06 18:55 by 52305043001
[¿¼ÑÐ] 331Çóµ÷¼Á +8 ÓÚÕ÷yz 2026-04-05 8/400 2026-04-06 00:54 by fmesaito
[¿¼ÑÐ] ²ÄÁÏר˶322·Ö +11 ¹þ¹þ¹þºðºðºð¹þ 2026-04-02 11/550 2026-04-04 23:37 by ÓÀ×ÖºÅ
[¿¼ÑÐ] ÇóÉúÎïѧѧ˶µ÷¼Á¡ª¡ª364·Ö +7 ÔÆ¶äåÞÍäÖ¸ÄÏ 2026-04-04 7/350 2026-04-04 22:49 by zhyzzh
[¿¼ÑÐ] 286Çóµ÷¼Á +3 ²Ýľ²»ÑÔ 2026-04-04 3/150 2026-04-04 22:40 by lbsjt
[¿¼ÑÐ] 325Çóµ÷¼Á +4 ´º·ç²»½èÒâ 2026-04-04 4/200 2026-04-04 22:08 by à£à£à£0119
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÄÏʦ·¶361·Ö£¬»¯Ñ§Çóµ÷¼Á +7 Nicole88888 2026-04-01 7/350 2026-04-04 18:28 by macy2011
[¿¼ÑÐ] 348·Ö»·¾³¹¤³Ì¡¤µ÷¼Á +10 ÎâÑå׿24k 2026-04-03 11/550 2026-04-04 14:19 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] ×Ü·Ö328ÉúÎïÓëÒ½Ò©¿¼ÊýѧÇóµ÷¼Á +7 aaadim 2026-04-02 9/450 2026-04-03 22:53 by syh9288
[¿¼ÑÐ] Êý¶þÓ¢¶þ348Çóµ÷¼Á +4 hxdzj1 2026-04-03 5/250 2026-04-03 21:25 by zhq0425
[¿¼ÑÐ] µ÷¼Á +7 ìíáº. 2026-04-02 7/350 2026-04-03 09:11 by »¨ß»¹Ç·600
[¿¼ÑÐ] 326Çóµ÷¼Á +3 9ahye 2026-04-02 4/200 2026-04-03 08:43 by Jaylen.
[¿¼ÑÐ] Ò»Ö¾Ô¸9³õÊÔ366 ±¾Ë«·ÇÇóµ÷¼Á +4 ÔËÆøÀ´µÃÈôÓÐËÆÎ 2026-04-02 4/200 2026-04-02 09:56 by guanxin1001
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +11 Ò»ÑùYWY 2026-03-31 11/550 2026-04-01 22:25 by zhouyuwinner
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û